Image may be NSFW.
Clik here to view.
Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus.
The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides guidance for injection using the Basaglar KwikPen, injection demo kits and educational videos.
Get the full story at our sister site, Drug Delivery Business News.
The post Lilly, Boehringer’s Basaglar long-acting insulin now available in the U.S. appeared first on MassDevice.
